Oriel Therapeutics, Inc. to Present at Major International Dry Powder Technology Conference.RESEARCH TRIANGLE PARK Research Triangle Park, research, business, medical, and educational complex situated in central North Carolina. It has an area of 6,900 acres (2,795 hectares) and is 8 × 2 mi (13 × 3 km) in size. Named for the triangle formed by Duke Univ. , N.C. -- Oriel Therapeutics announces today that Dr. Timm Crowder, Vice President Powder Technology, will be presenting results of early formulation development studies on a novel combination dry powder inhaler The Dry Powder Inhaler is generally a proprietary device to deliver medications for the treatment or maintenance management of respiratory diseases and conditions. These conditions or diseases may include Asthma, Bronchitis, Emphysema, COPD and Diabetes. , powered by Oriel's patented vibrational drug delivery technology, in London on June 30th (Presentation Title: Oriel Therapeutics' Active DPI (Dots Per Inch) The measurement of the resolution of display and printing systems. A typical CRT screen provides 96 dpi, which provides 9,216 dots per square inch (96x96). Flat panel displays from 110 to 200 dpi have also been developed. simplifies formulation activities for combination therapy). The meeting, organized by Management Forum is an annual meeting to showcase some of the most significant events that are occurring in DPI development and application and includes talks on the use of DPIs for both local and systemic delivery. Oriel's Chief Scientific Officer and Chair of the Oriel Scientific Advisory Board, Professor Anthony Hickey, said, "This event is a leading International inhalation conference and we are delighted to have the opportunity to present our technology and early development results to our peers. We believe these data demonstrate the capability of the Oriel technology to be used to develop novel combination drug therapies that require minimal formulation efforts." About Oriel Therapeutics Based in Research Triangle Park, Oriel Therapeutics, Inc. is an inhaled in·hale v. in·haled, in·hal·ing, in·hales v.tr. 1. To draw (air or smoke, for example) into the lungs by breathing; inspire. 2. drug delivery company based on innovative technology for aerosolizing powders using the application of powder-specific electrical frequencies. Oriel was recently named to the BioTech 15, a list featuring some of the region's most promising high-growth biotech companies. The magazine selected the companies using criteria such as uniqueness of the technology, the management team and the potential market size. The list focuses on early-stage companies that have raised less than $40 million. Utilizing technology developed at the University of North Carolina at Chapel Hill The University of North Carolina at Chapel Hill is a public, coeducational, research university located in Chapel Hill, North Carolina, United States. Also known as The University of North Carolina, Carolina, North Carolina, or simply UNC , Oriel is developing dry powder inhaler (DPI) products with their own energy source for efficient drug delivery to the lungs to better treat a range of respiratory diseases including asthma and COPD COPD chronic obstructive pulmonary disease. COPD abbr. chronic obstructive pulmonary disease Chronic obstructive pulmonary disease (COPD) . Oriel Therapeutics also has a Powder Metering business unit that is developing proprietary powder fluidization Fluidization The processing technique employing a suspension or fluidization of small solid particles in a vertically rising stream of fluid—usually gas—so that fluid and solid come into intimate contact. technology for precision powder metering of non-free flowing powders. Oriel has 3 issued US patents as well as 14 US and associated international patent applications pending, for various aspects of the aerosolization and powder fluidization technology. For more information visit www.orieltherapeutics.com |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion